United States Government Publishing Office publisher pbl distributor dst United States National Archives and Records Administration Office of the Federal Register author aut Government Organization text government publication eng FR Regulatory Information 2016_register executive 2016-05-18 article Notices D09002ee1c7f62d23 D09002ee1c7f62d99 United States Department of Health and Human Services originator org United States Government Agency or Subagency United States National Institutes of Health originator org United States Government Agency or Subagency This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7, that the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-Up Exclusive Patent License to practice the inventions embodied in the following patent applications to Chimeron Bio Corporation, a company incorporated under the laws of Delaware and having an office in Philadelphia, PA. Intellectual Property: U.S. Provisional Patent Application No.: 61/ 615,687 Entitled "Delivery of Packaged RNA in Mammalian Cells" HHS Ref. No.: E-264-2011/0-US-01 Filed March 26, 2012; International Patent Application No.: PCT/US2013/031876 Entitled "Delivery of Packaged RNA in Mammalian Cells" HHS Ref. No.: E-264-2011/0-PCT-02 Filed March 15, 2013; Australian Patent Application No.: 2013-240248 Entitled "Delivery of Packaged RNA in Mammalian Cells" HHS Ref. No.: E-264- 2011/0-AU-03 Filed October 17, 2014; European Patent Application No.: 13712661.1 Entitled "Delivery of Packaged RNA in Mammalian Cells" HHS Ref. No.: E-264-2011/0-EP-04 Filed October 24, 2014; Japanese Patent Application No.: 2015-503322 entitled "Delivery of Packaged RNA in Mammalian Cells" HHS Ref. No.: E-264-2011/0-JP-05 Filed September 25, 2014; U.S. Patent Application No.: 14/388,441 Entitled Delivery of Packaged RNA in Mammalian Cells" HHS Ref. No.: E-264-2011/0-US-06 Filed September 26, 2014; U.S. Provisional Patent Application No.: 61/ 916,394 Entitled "Cancer Immunotherapy: Delivery HLA-11 using VLP- Replicon" HHS Ref. No.: E-050-2014/0-US-01 Filed December 16, 2013; International Patent Application No.: PCT/US2014/070552 Entitled "Cancer Immunotherapy: Delivery HLA-11 using VLP-Replicon" HHS Ref. No.: E-050-2014/0-PCT-02 Filed December 16, 2014; The patent rights to these inventions have been assigned to the Government of the United States of America. The prospective exclusive start-up licensed territory may be worldwide and the field of use may be limited to: "Use of virus like particles comprising MHCII and CD80 for the treatment of breast cancer, lung cancer, melanoma, pancreatic cancer, and hepatocellular cancer." 81 FR 31250 https://www.govinfo.gov/app/details/FR-2016-05-18/2016-11661 2016-11661 fr18my16-53 4140-01-P https://www.govinfo.gov/app/details/FR-2016-05-18/2016-11661 https://www.govinfo.gov/content/pkg/FR-2016-05-18/html/2016-11661.htm https://www.govinfo.gov/content/pkg/FR-2016-05-18/pdf/2016-11661.pdf 2 p. 31250 31251 81 FR 31250 Prospective Grant of Start-up Exclusive License: Development of Virus Like Particles for the Treatment of Breast Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, and Hepatocellular Cancer; Federal Register Vol. 81, Issue NOTICE 2016-11661 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health 2016-06-02 4140-01-P 2016-11661 Notice.

This notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR part 404.7, that the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, is contemplating the grant of a Start-Up Exclusive Patent License to practice the inventions embodied in the following patent applications to Chimeron Bio Corporation, a company incorporated under the laws of Delaware and having an office in Philadelphia, PA. Intellectual Property: U.S. Provisional Patent Application No.: 61/ 615,687 Entitled "Delivery of Packaged RNA in Mammalian Cells" HHS Ref. No.: E-264-2011/0-US-01 Filed March 26, 2012; International Patent Application No.: PCT/US2013/031876 Entitled "Delivery of Packaged RNA in Mammalian Cells" HHS Ref. No.: E-264-2011/0-PCT-02 Filed March 15, 2013; Australian Patent Application No.: 2013-240248 Entitled "Delivery of Packaged RNA in Mammalian Cells" HHS Ref. No.: E-264- 2011/0-AU-03 Filed October 17, 2014; European Patent Application No.: 13712661.1 Entitled "Delivery of Packaged RNA in Mammalian Cells" HHS Ref. No.: E-264-2011/0-EP-04 Filed October 24, 2014; Japanese Patent Application No.: 2015-503322 entitled "Delivery of Packaged RNA in Mammalian Cells" HHS Ref. No.: E-264-2011/0-JP-05 Filed September 25, 2014; U.S. Patent Application No.: 14/388,441 Entitled Delivery of Packaged RNA in Mammalian Cells" HHS Ref. No.: E-264-2011/0-US-06 Filed September 26, 2014; U.S. Provisional Patent Application No.: 61/ 916,394 Entitled "Cancer Immunotherapy: Delivery HLA-11 using VLP- Replicon" HHS Ref. No.: E-050-2014/0-US-01 Filed December 16, 2013; International Patent Application No.: PCT/US2014/070552 Entitled "Cancer Immunotherapy: Delivery HLA-11 using VLP-Replicon" HHS Ref. No.: E-050-2014/0-PCT-02 Filed December 16, 2014; The patent rights to these inventions have been assigned to the Government of the United States of America. The prospective exclusive start-up licensed territory may be worldwide and the field of use may be limited to: "Use of virus like particles comprising MHCII and CD80 for the treatment of breast cancer, lung cancer, melanoma, pancreatic cancer, and hepatocellular cancer."

Only written comments and/or applications for a license which are received by the NCI Technology Transfer Center on or before June 2, 2016 will be considered. Start-up Exclusive License Approvals: Development of Virus Like Particles for the Treatment of Breast Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, and Hepatocellular Cancer , lauren.nguyen-antczak@nih.gov Vol. 81, no. 96 Office of the Federal Register, National Archives and Records Administration 2016-05-18 continuing daily deposited born digital 335 p. Table of Contents: AE 2.7: GS 4.107: AE 2.106: KF70.A2 https://www.govinfo.gov/app/details/FR-2016-05-18 P0b002ee18f7b0612 0097-6326 0042-1219 0364-1406 769-004-00000-9 000582072 f:fr18my16 https://www.govinfo.gov/app/details/FR-2016-05-18 https://www.govinfo.gov/content/pkg/FR-2016-05-18/pdf/FR-2016-05-18.pdf https://www.govinfo.gov/content/pkg/FR-2016-05-18/xml/FR-2016-05-18.xml fdlp 31161 31487 DGPO 2016-05-18 2024-06-01 FR-2016-05-18 machine generated eng FR FR-2016-05-18 81 96